Glaxo to reduce U.S. sales force
times wire services
British drug maker GlaxoSmithKline is restructuring its U.S. operations, starting with reducing its U.S. sales force by 1,000, following many of its top competitors in eliminating sales jobs.
The world’s No. 2 drug maker by revenue also will switch from having dual U.S. headquarters, in Philadelphia and in Research Triangle Park, N.C., to operating just the North Carolina headquarters.
Spokeswoman Mary Anne Rhyne said the headquarters change was meant to eliminate confusion and was largely symbolic. There are currently no plans to cut jobs in Philadelphia related to the headquarters move, she said.
